PharmAust collaborates with Walter and Eliza Hall Institute to test antiviral potential of MPL in HTLV-1

Retrieved on: 2021-07-12 00:00:00

Tags for this article:

Medical specialties

Health

Clinical medicine

Pandemics

Infectious causes of cancer

Sexually transmitted diseases and infections

Human T-lymphotropic virus 1

Human T-lymphotropic virus

Click the tags to see associated articles and topics

PharmAust collaborates with Walter and Eliza Hall Institute to test antiviral potential of MPL in HTLV-1. View article details on hiswai:

Excerpt

PharmAust (ASX: PAA) will evaluate the impact of its monepantel (MPL) drug on ... The virus has a high incidence in Japan with several central Australian ... #1 site for market news & information on ASX listed small cap companies.

Article found on: smallcaps.com.au

View Original Article